Felycin®-CA1 (sirolimus delayed-release tablets) Redefines Feline Cardiac Care
First-in-class oral management option for hypertrophic cardiomyopathy earns FDA conditional approval, changing the landscape of feline medicine
PENSACOLA, Fla., June 12, 2025 /PRNewswire/ -- Pegasus Laboratories/PRN Pharmacal has announced the addition of a new FDA conditionally approved drug, Felycin®-CA1 (sirolimus delayed-release tablets), to their portfolio. This first-in-class therapy is designed to manage ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM), representing a major milestone in feline medicine and offering new hope to owners of cats living with this progressive and often fatal disease.
HCM is a heart condition which causes the muscular walls of a cat's heart to become abnormally thick, reducing the heart's ability to pump blood efficiently. This can lead to heart failure and other complications, including sudden death. Many cats with HCM remain subclinical for years, while others may develop symptoms of congestive heart failure.
While the exact cause of the disease is not fully understood, HCM is more common in certain breeds, including British Shorthair, Chartreux, Maine Coon, Persian, Ragdoll, and Sphynx cats. Researchers have also identified mutations in various cardiac genes causing HCM in several of these breeds.
'Felycin-CA1 signals a turning point in feline medicine by providing veterinarians a much-needed option to help slow the progression of HCM beyond just managing the disease,' said Dr. Heather Davis, DVM, PhD, DACVS-LA, Director of Clinical Affairs and Veterinary Services at Pegasus Laboratories. 'It is a major step forward for cats and the people who care for them. For the first time, we're changing the conversation around what's possible in feline heart care.'
FDA conditional approval of Felycin®-CA1 follows results from a multi-center study demonstrating its ability to improve key cardiac outcomes, while also proving its ease of use in everyday veterinary practices.
'Veterinarians have long-needed options beyond palliative care when it comes to feline HCM,' said Dr. Joshua Stern, DVM, PhD, DACVIM. 'With Felycin-CA1, we can offer a therapy that has been shown in our initial clinical trial to stop progressive heart muscle thickening, slowing disease progression. We believe this management option marks the beginning of a new chapter where innovation in feline therapeutics becomes the rule, not the exception.'
Felycin®-CA1 is slated to be available beginning August 2025, in 0.4 mg, 1.2 mg, and 2.4 mg tablet strengths by prescription from a licensed veterinarian. Cats should be screened for pre-existing liver disease before starting the medication, and it should not be used in cats with pre-existing liver disease or diabetes mellitus.
About Pegasus Laboratories
Pegasus Laboratories, Inc., based in Pensacola Florida, is a pharmaceutical development and manufacturing organization focused on innovative products to treat chronic conditions in cats, dogs, and horses. Our products go to market under the PRN® Pharmacal brand. We also serve as a contract manufacturer for the Animal Health industry. We were founded in 1985 and acquired by PBI-Gordon Companies, Inc. in 1999.
View original content to download multimedia: https://www.prnewswire.com/news-releases/felycin-ca1-sirolimus-delayed-release-tablets-redefines-feline-cardiac-care-302479557.html
SOURCE Pegasus/PRN Pharmacal
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential. It reported interim Week 26 data from its Phase 2 COACH Trial, confirming that combining TransCon hGH (lonapegsomatropin) with TransCon CNP (navepegritide) raised annualized growth velocity (AGV) and height Z-scores in children with achondroplasia. A close-up view of a hand manipulating a syringe while delivering TransCon CNP into a tumor. A mean AGV of 9.14 cm/year and a +0.53 Z-score rise were attained by treatment-naïve youngsters (N=12). Children (N=9) treated with TransCon CNP in the past achieved an AGV of 8.25 cm/year with a +0.44 Z-score improvement. The majority of side effects were modest, and safety remained consistent with monotherapies. The COACH Trial is the first to assess this combination in kids between the ages of two and eleven. While TransCon CNP is undergoing FDA priority review, TransCon hGH is approved as SKYTROFA® for juvenile growth hormone insufficiency. The treatment focuses on the FGFR3-CNP signaling imbalance that is at the heart of achondroplasia, a disorder that affects more than 250,000 people worldwide. It is anticipated that the results of week 52 and a scheduled Phase 3 trial in Q4 2025 will further clarify efficacy and long-term benefits. The biopharmaceutical business Ascendis Pharma A/S (NASDAQ:ASND) uses its TransCon technology platform to significantly improve patient outcomes. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.
Medscape
an hour ago
- Medscape
Diversity Gap Persists in Key Trials for Psoriatic Arthritis
An analysis of 29 pivotal drug trials for psoriatic arthritis revealed significant racial disparities, with White individuals making up the majority of trial participants, whereas Asian, Black, and other racial groups remained underrepresented. Geographic disparities in participant inclusion were also observed, with trial sites primarily located in North America and Europe. METHODOLOGY: Researchers conducted a descriptive epidemiologic study to assess the gaps in reporting of racial, ethnic, and geographic data of participants enrolled in pivotal US clinical trials of biologic and targeted synthetic disease-modifying antirheumatic drugs for psoriatic arthritis. They collected data on 14,845 participants enrolled in 29 trials with start dates from April 2000 to April 2019, using three primary public sources: Journal publications, the Drugs@FDA database, and Overall, 16 drugs with varying mechanisms were assessed in these trials: Seven trials each of TNF inhibitors and interleukin 17A or 17A/F inhibitors, four trials each of JAK inhibitors and interleukin 23 inhibitors, three trials of phosphodiesterase 4 inhibitors, and two trials each of cytotoxic T-lymphocyte antigen immunoglobulin and interleukin 12/23 inhibitors. TAKEAWAY: Data on race were reported in 93% of trials, with the most frequent reporting in journal publications (86%), although 46% of them reported the proportion of only White participants. Among participants for whom data on race were available, 92% were White, 5% were Asian, 0.6% were Black, 0.3% were American Indian/Alaska Native, and 0.1% were Native Hawaiian/Pacific Islander individuals. Ethnicity was formally reported in only 41% of trials. The reporting of both race and ethnicity improved over time, reaching full coverage (eight of eight trials) on between 2016 and 2020. Among participants for whom data on ethnicity were available, 11% were Hispanic or Latino individuals. Within the US, the highest participation was reported from Texas (24 trials), Florida and Pennsylvania (22 each), California (20), and Alabama (18), with participation in clinical trials strongly correlated with state population size (correlation coefficient, 0.78; P < .0001). Trial sites were primarily located in North America and Europe, with limited representation in Asia, Africa, and Latin America. IN PRACTICE: 'Standardizing and mandating race and ethnicity reporting across data sources is crucial to ensure transparency and equity. Tailored and multifaceted recruitment strategies are essential to increase diversity and ensure the generalizability of trial results, ultimately aiding clinicians to provide the most effective and informed treatment options for all patients,' the authors wrote. SOURCE: This study was led by Mathieu Choufani, MD, Brigham and Women's Hospital, Boston. It was published online on May 19, 2025, in Arthritis Care & Research . LIMITATIONS: This study relied on the US-centric Office of Management and Budget categories for data on race and ethnicity, which may not have represented international populations. Definitions of categories were inconsistent across data sources. Site-level enrollment details were lacking. The analysis was focused solely on pivotal trials for FDA-approved drugs. DISCLOSURES: This study had no specific outside funding source. One author reported receiving consulting fees and grants from various pharmaceutical organizations and being a member of the board of directors for the Spondyloarthritis Research and Treatment Network. Another author reported owning stocks in UCB and Abcuro.
Yahoo
an hour ago
- Yahoo
FDA approves label expansion of AbbVie hepatitis C therapy
The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie's Mavyret (glecaprevir/pibrentasvir) for treating adults and paediatric patients three years and older with acute or chronic hepatitis C virus (HCV) infection. The extended indication for this oral pangenotypic direct-acting antiviral (DAA) therapy involves those who have the infection without cirrhosis or with compensated cirrhosis. The therapy is the first and only DAA treatment approved for this patient group. HCV is a blood-borne infectious disease that can lead to serious liver complications. The agency's approval is based on data from a Phase III, single-arm, prospective multicentre trial that evaluated the efficacy and safety of an eight-week treatment of the therapy in adults with acute HCV infection. Findings from the trial demonstrated that the therapy is a highly efficacious treatment option. AbbVie research and development executive vice-president and chief scientific officer Roopal Thakkar stated: "Mavyret has treated more than one million patients with HCV, but we recognise that a significant need remains for patients with acute infection. "The label expansion for Mavyret, coupled with the implementation of 'test and treat' models of care, serves as a tool to support the public health community in treating more patients and bringing us closer to achieving the global 2030 elimination goal." Mavyret had also secured a breakthrough therapy designation from the US regulator for acute HCV. This status expedites the development and review of medicines intended to treat serious conditions when preliminary clinical evidence suggests substantial improvement over current therapies. In May 2025, AbbVie signed a partnership and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to access its small interfering RNA platform. "FDA approves label expansion of AbbVie hepatitis C therapy" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
